Clinical trials: Depressive Disorder
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit…
- Trial name
- NCT04446039
- Testing
- Escitalopram, Paroxetine, Fluoxetine
- Where
- South Korea
- Volunteers
- 370,212 people
- Sponsor
- Pfizer
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression, Suicidal Ideation
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SevereBD (NCT03396601)
- Testing
- Ketamine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- NeuroRx, Inc.
Cancer Pain
Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)
The purpose of this study is to evaluate the relationship between cancer pain and risk of depression among cancer patients.
- Trial name
- NCT01402830
- Testing
- Visual analogue scales (EVAs)
- Volunteers
- 271 people
- Sponsor
- Janssen-Cilag, S.A.
Major Depressive Disorder
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD).
- Trial name
- NCT06357832
- Testing
- Brainsway Deep TMS System
- Where
- 9 sites in United States, India and 1 more
- Volunteers
- 104 people
- Sponsor
- Brainsway
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Panic Disorder, Depression
Drug Use Investigation of Jzoloft.
The objective of this surveillance is to collect information about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00605865
- Testing
- Sertraline hydrochloride
- Volunteers
- 2,272 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depression - Major Depressive Disorder
Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)
To determine the bioequivalence of 2 tablets of 25 mg sustained release (SR) formulation of DVS and 1 tablet of 50 mg SR formulation of DVS under fed and fast conditions.
- Trial name
- NCT01190514
- Testing
- desvenlafaxine succinate sustained release
- Where
- Belgium
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Postpartum Depression
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.
- Trial name
- NCT05059600
- Testing
- ZULRESSO®
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder With Mixed Features
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
- Trial name
- RESOLVE 1 (NCT01421134)
- Testing
- Lurasidone
- Where
- 43 sites in United States, Russia and 3 more
- Volunteers
- 211 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy
The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.
- Trial name
- NCT00095134
- Testing
- risperidone
- Where
- 70 sites in United States
- Volunteers
- 630 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06423781
- Testing
- BHV-7000
- Where
- 66 sites in United States
- Volunteers
- 233 people
- Sponsor
- Biohaven Therapeutics Ltd.
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Depressive Disorder, Major
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured…
- Trial name
- NCT01141400
- Volunteers
- 48,865 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Opiate Induced Respiratory Depression
Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil.
- Trial name
- NCT02735629
- Testing
- CX1739 - 300 mg, CX1739 - 600 mg, CX1739 - 900 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- RespireRx
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Major Depressive Disorder
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
- Trial name
- NCT00277823
- Testing
- DVS-SR 50 mg, DVS-SR 100 mg
- Where
- 25 sites in United States
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer